Obesity: A rational target for managing diabetes mellitus

Growth Hormone and IGF Research

Volumn 11, Issue SUPPL. 1, 2001, Pages

  Mooradian, Arshag D ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Drug therapy; Insulin resistance; Obesity; Orlistat; Sibutramine; Weight loss

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; HUMANS; LACTONES; OBESITY; PREVALENCE; WEIGHT LOSS;

EID: 0035381046     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(01)80013-7     Document Type: Review

References (45)

1. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999; 282: 1519-1522.
2. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
3. Morris RD, Rimm DL, Hartz AJ, Kalkhoff RK, Rimm AA. Obesity and heredity in the etiology of non-insulin-dependent diabetes mellitus in 32,662 adult white women. Am J Epidemiol 1989; 130: 112-121.
4. Bray GA. Obesity increases risk for diabetes. Int J Obes Relat Metab Disord 1992; 16 (Suppl 4): S13-S17.
5. Felber JP, Acheson KJ, Tappy L. From obesity to diabetes. New York, NY: Wiley, 1993.
6. Mooradian AD, Kalis J, Nugent CA. The nutritional status of ambulatory elderly type II diabetic patients. Age 1990; 13: 87-89.
7. Mooradian AD, Osterweil D, Petrasek D, Morley JE. Diabetes mellitus in elderly nursing home patients. A survey of clinical characteristics and management. J Am Geriatr Soc 1988; 36: 391-396.
8. Knowler WC, Pettitt DJ, Savage PJ, Bennett PH. Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes. Am J Epidemiol 1981; 113: 144-156.
9. Ohlson LO, Larsson B, Svärdsudd K, et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow up of the participants in the study of men born in 1913. Diabetes 1985; 34: 1055-1058.
10. Cassano PA, Rosner B, Vokonas PS, Weiss ST. Obesity and body fat distribution in relation to the incidence of non-insulin-dependent diabetes mellitus. A prospective cohort study of men in the Normative Aging Study. Am J Epidemiol 1992; 136: 1474-1486.
11. Bosello O, Zamboni M, Armellini F, Todesco T. Biological and clinical aspects of regional body fat distribution. Diab Nutr Metab 1993; 6: 163-171.
12. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.
13. Chan JM, Rimm EB, Colditz GA, Stampfer JM, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-969.
14. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983; 72: 1737-1747.
15. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-2865.
16. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidyl-inositol 3-kinase activity. J Clin Invest 1999; 103: 253-259.
17. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995; 44: 863-870.
18. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-138.
19. Mason TM, Goh T, Tchipashvili V, et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 1999; 48: 524-530.
20. Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000; 141: 3388-3396.
21. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
22. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity-induced insulin resistance. Science 1996; 271: 665-668.
23. Mooradian AD, Reed RL, Meredith KE, Scuderi P. Serum levels of tumor necrosis factor and IL-1α and IL-1β in diabetic patients. Diabetes Care 1991; 14: 63-65.
24. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-alpha concentrations in a Native Canadian population with high rate of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 272-278.
25. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-1188.
26. Taylor SI, Barr V, Reitman M. Does leptin contribute to diabetes caused by obesity? Science 1996; 274: 1151-1152.
27. Cases JA, Gabriely I, Ma HX, et al. Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo. Diabetes 2001; 50: 348-352.
28. Mooradian AD, Chehade J, Hurd R, Haas MJ. Monosaccharide-enriched diets cause hyperleptinemia without hypophagia. Nutrition 2000; 16: 439-441.
29. Mooradian AD, Chehade J. Serum leptin response to endogenous hyperinsulinemia in aging rats. Mech Ageing Dev 2000; 115: 101-106.
30. McGregor GP, DeSaga JF, Ehlenz K, et al. Radioimmunological measurement of leptin in plasma of obese and diabetic human subjects. Endocrinology 1996; 137: 1501-1504.
31. Mantzoros CS. The role of leptin and hypothalamic neuropeptides in energy homeostasis: update on leptin in obesity. Growth Horm IGF Res 2001; 11 (Suppl A): 85-90.
32. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
33. Wing RR, Blair E, Bononi P, Marcus M, Watanabe R, Bergman R. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994; 17: 30-36.
34. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749-1753.
35. Heath GW, Wilson RH, Smith J, Leonard BE. Community-based exercise and weight control: diabetes risk reduction and glycemic control in Zuni Indians. Am J Clin Nutr 1991; 53: 1462S-1464S.
36. Uusitupa M, Louheranta A, Lindstrom J, et al. The Finnish Diabetes Prevention Study. Br J Nutr 2000; 83 (Suppl 1): S137-S142.
37. Diabetes Prevention Program Research Group. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999; 22: 623-634.
38. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995; 141: 1128-1141.
39. Bray GA, Ryan DH, Gordon D, et al. A double-blind, randomized, placebo-controlled trial of sibutramine. Obes Res 1996; 4: 263-270.
40. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-2191.
41. Heath MJ, Chong E, Weinstein SP, Seaton TB. Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus. Diabetes 1999; 48 (Suppl): A306.
42. Sjöström L, Rissanen A, Andersen T, et al. Randomised, placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-172.
43. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. For the Orlistat Primary Care Study Group. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160-167.
44. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized, double-blind study. Diabetes Care 1998; 21: 1288-1294.
45. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321-1326.